Moderna (NASDAQ:MRNA) is in talks with Japan's Ministry of Health, Labour and Welfare to sell 40 million doses of its coronavirus vaccine mRNA-1273. If the sides can come to terms -- and the vaccine is ultimately approved in the country -- Japan-based Takeda Pharmaceutical (NYSE:TAK) will distribute the vaccine starting in the first half of 2021.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,